A New Strategy to Fight Treatment-Resistant Cancer

Karmele Valencia.

Fundación para la Investigación Médica Aplicada (FIMA/CIMA), Spain.

Many patients with advanced cancer eventually lose access to effective treatment because tumours become resistant. DSTYK is a protein that helps protect cancer cells and is associated with tumour progression and resistance to chemotherapy and immunotherapy. This project aims to develop the first small-molecule inhibitor of this currently undruggable target.

Researchers will design and optimise a precision medicine that blocks DSTYK in cancers in which the protein is recurrently altered. Laboratory studies using genetic inhibition have already shown anti-tumour activity and increased sensitivity to established treatments. The programme will seek a partner-ready preclinical asset with confirmed target engagement, strong activity in animal models and a clear route towards clinical development.

A DSTYK inhibitor could provide monotherapy or combination options for patients with lung, breast, liver and other common cancers with limited alternatives. By addressing a mechanism of resistance, the treatment may extend the benefit of existing therapies and reduce complications linked to disease progression. The project therefore addresses a significant unmet medical need with potential clinical, social and economic value.

STAGE 1